Viapath reports continued growth despite contract upheaval

Pathology provider Viapath continued to deliver strong growth in 2019 despite political uncertainty over Brexit and the re-tendering of its core contract. The Group, which saw its private sector partner Serco withdraw subsequent to the year-end after Synlab was announced preferred bidder for the new contract with South East London STP (SEL STP), reported a…

You must be a HM Subscriber to view this content. Please log in or subscribe below.

Subscribe Now »